Page 2 - Strides Pharma Science

Strides Pharma posts Rs 43 cr Q4 profit vs Rs 207 cr loss a year ago

Company to launch generic products to aid Covid-19 treatment in India, first being Liposomal Amphotericin B to treat black fungus

Stelis CEO steps down after Indian firm signs deal for Russia vaccine

Roger Lias, who accepted the CEO job at unlisted Stelis in late 2019 when the pandemic was in its early stages, left on March 31

Strides Pharma Science arm gets USFDA nod for HIV treatment medicine

Strides Pharma Science said its step-down wholly-owned subsidiary, has received approval from the USFDA for Emtricitabine and Tenofovir Disoproxil Fumarate tablets, used to treat HIV

Strides dips 6% from high on profit booking as Aditya Puri joins as advisor

In the past six months, the stock has zoomed 130 per cent, as compared to 33 per cent rally in the S&P BSE Sensex

Strides Pharma Science gets USFDA nod for generic Prednisone tablets

Strides Pharma Science Ltd on Monday said it has received approval from the US health regulator for its generic version of Prednisone tablets, prescribed for a variety of conditions, including allergies, respiratory illness and arthritis. The approval for Prednisone tablets by the US Food & Drug Administration (USFDA) granted to the company's step-down wholly owned subsidiary, Strides Pharma Global Pte Limited, Singapore, is for multiple strengths of 2.5 mg and 5 mg, Strides Pharma Science said in a regulatory filing. The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Deltasone tablets, 2.5 mg and 5 mg, of Pharmacia and Upjohn Co, it added. Citing IQVIA MAT September 2020 data, the company said the US market for Prednisone Tablets USP, 2.5 mg and 5 mg is approximately USD 30 million. "The product will be manufactured at the company's flagship facility at Bengaluru and will be marketed by Strides Pharma Inc in the US market," it ...

Here are the top stock picks by Nilesh Jain of Anand Rathi Shares

The stock has formed a bearish Harami candlestick pattern on the daily chart which is considered as a bearish reversal pattern.

Strides Pharma shares zoom 8% on US FDA approval for Ursodiol tablets

Ursodiol is used for treatment of patients with primary biliary cirrhosis (PBC)

Strides Pharma Science Q1 net profit jumps over 4-fold to Rs 102 cr

Drug firm Strides Pharma Science on Wednesday reported over four-fold rise in its consolidated net profit at Rs 101.84 crore for the quarter ended June 30, 2020, mainly on account of a one-time gain. The company had posted a net profit of Rs 25.36 crore in the corresponding period of the previous fiscal, Strides Pharma Science said in a filing to the BSE. Total income of the company stood at Rs 794.10 crore in the quarter under consideration. It was at Rs 696.05 crore in the same period a year ago. The company had a gain of Rs 44.91 crore, shown as an exceptional item, in the quarter ended June this year. "We have reported strong performance across all our business in Q1 FY21 despite significant disruptions and ambiguity in the business environment due to COVID-19," Strides Pharma Science MD & CEO R Ananthanarayanan said. "While our manufacturing and supply chain continue to remain steady without any significant disruptions, we remain cautiously optimistic on the outlook of our ..

Sun Pharma to test pancreatitis drug in Covid-19 patients in India

Sun Pharma it has initiated manufacturing of the active pharmaceutical ingredient and the finished product of the drug using technology from its unit, Pola Pharma Japan.

Strides posts pre-tax loss of Rs 217 cr in Q4 as ranitidine ban in US bites

Ranitidine was a $9 million business for Strides in the first half of FY20

Strides Pharma commences export of Favipiravir tablets; stock surges 15%

The drug has demonstrated positive outcomes, including a reduction in the duration of Covid-19 and improved lung conditions for the patients

Strides Pharma Science gets USFDA nod for generic anti-bacterial capsules

The product is a generic version of Achromycin V Capsules, 250 mg and 500 mg, of Avet Pharmaceuticals (previously Heritage Pharmaceuticals)

Strides Pharma Science inks deal with Pharmaceutics to buy 18 ANDAs for US

With access to these products, Strides will significantly expand its niche offerings on its front-end, which has grown multi-fold to attain a quarterly revenue size of $66 million

Strides Pharma posts threefold rise in profit-before-tax at Rs 103.6 crore

The Bengaluru-headquartered company posted a 358 per cent rise in net profit at 101 crore as compared to the corresponding quarter of the previous financial year

Strides Pharma Science may resume Ranitidine drug sale in US market

Strides' Ranitidine tablets 300 mg is within the acceptable limits for N-nitrosodimethylamine (NDMA) of 96 nanograms per day or 0.32 ppm

Strides Pharma likely to launch affordable insulin from Stelis stable

The Bengaluru-headquartered company believes Stelis could be a disruptor in insulin accessibility and affordability.

Strides Pharma resumes sales of antacid drug Ranitidine in Australia

Strides predominantly sells Ranitidine tablets in the US markets

Strides Pharma dips 6% after it temporarily suspends Ranitidine sales in US

The stock of pharmaceuticals company was trading lower for the fifth straight day, slipping 14 per cent, as against a 2 per cent rise in the benchmark S&P BSE Sensex during the week.

Strides Pharma soars 12% after Co announces JV with Chinese firm

Strides Pharma Global Pte (Singapore) and Sun Moral International (Hong Kong), a wholly-owned subsidiary of Sihuan Pharmaceutical Holdings, have entered into a JV to form called Sihuan Strides.

USFDA finds adulteration, 'significant violations' at Strides Pharma plant

The regulator found 'significant violations' of current good manufacturing practice regulations at Strides Pharma's plant in Puducherry